The Impact of Label Changes (Boxed Warning) on Real-World Febuxostat Utilization in Patients with Gout: A Cross-Sectional Drug Utilization Study

Overview of attention for article published in Rheumatology and Therapy, July 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#31 of 515)
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 2 news outlets

twitter: 5 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 4 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

Febuxostat Utilization Declines Following Label Change, Despite Favorable Benefit-Risk Profile

Rheumatology Advisor, 09 Aug 2023

The number of new users of febuxostat (allopurinol-naïve) and prevalent new users (prior allopurinol use) decreased following a…

Study Details Decline in Febuxostat Use Following FDA's Addition of Boxed Warning

HCP Live, 22 Jul 2023

Credit: Fotolia A new study is providing clinicians with a breakdown of the impact of 2019 label changes on real-world…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.